Escholarship@umms Cell and Developmental Biology Publications and Presentations Cell and Developmental Biology Targeting the Chromatin Remodeling Enzyme Brg1 Increases the Efficacy of Chemotherapy Drugs in Breast Cancer Cells Repository Citation Targeting the Chromatin Remodeling Enzyme Brg1 Increas

Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells" Creative Commons License This work is licensed under a Creative Commons Attribution 3.0 License. All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. ABSTRACT Brahma related gene product 1 (BRG1) is an ATPase that drives the catalytic activity of a subset of the mammalian SWI/SNF chromatin remodeling enzymes. BRG1 is overexpressed in most human breast cancer tumors without evidence of mutation and is required for breast cancer cell proliferation. We demonstrate that knockdown of BRG1 sensitized triple negative breast cancer cells to chemotherapeutic drugs used to treat breast cancer. An inhibitor of the BRG1 bromodomain had no effect on breast cancer cell viability, but an inhibitory molecule that targets the BRG1 ATPase activity recapitulated the increased drug efficacy observed in the presence of BRG1 knockdown. We further demonstrate that inhibition of BRG1 ATPase activity blocks the induction of ABC transporter genes by these chemotherapeutic drugs and that BRG1 binds to ABC transporter gene promoters. This inhibition increased intracellular concentrations of the drugs, providing a likely mechanism for the increased chemosensitivity. Since ABC transporters and their induction by chemotherapy drugs are a major cause of chemoresistance and treatment failure, these results support the idea that targeting the enzymatic activity of BRG1 would be an effective adjuvant therapy for breast cancer.

[1]  S. Armstrong,et al.  Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. , 2015, Molecular cell.

[2]  Simion I. Chiosea,et al.  The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation , 2015, Journal of cellular physiology.

[3]  S. Knapp,et al.  Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance , 2015, Science Advances.

[4]  Parantu K. Shah,et al.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. , 2015, Cancer research.

[5]  A. Jayaraman,et al.  Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  D. Reisman,et al.  Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation , 2015, Front. Oncol..

[7]  Songbin Fu,et al.  Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells. , 2015, Pharmacogenomics.

[8]  P. Hammerman,et al.  EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors , 2014, Nature.

[9]  B. Herbert,et al.  Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. , 2014, Anticancer research.

[10]  C. Roberts,et al.  Vulnerabilities of mutant SWI/SNF complexes in cancer. , 2014, Cancer cell.

[11]  M. Kornmann,et al.  BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. , 2014, European journal of cancer.

[12]  E. Denisov,et al.  The phenomenon of multi-drug resistance in the treatment of malignant tumors. , 2014, Experimental oncology.

[13]  Guofeng You,et al.  Drug transporters : molecular characterization and role in drug disposition , 2014 .

[14]  C. Vakoc,et al.  A rationale to target the SWI/SNF complex for cancer therapy. , 2014, Trends in genetics : TIG.

[15]  H. Ogiwara,et al.  Chromatin-regulating proteins as targets for cancer therapy , 2014, Journal of radiation research.

[16]  Ming Yu,et al.  Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.

[17]  B. van Calster,et al.  Triple negative breast cancer: clinical characteristics in the different histological subtypes. , 2013, Breast.

[18]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[19]  M. Dawson,et al.  Bromodomains as therapeutic targets in cancer. , 2013, Briefings in functional genomics.

[20]  P. Souček,et al.  The expression profile of ATP-binding cassette transporter genes in breast carcinoma. , 2013, Pharmacogenomics.

[21]  Junnian Zheng,et al.  BRG1 Is a Prognostic Marker and Potential Therapeutic Target in Human Breast Cancer , 2013, PloS one.

[22]  A. Imbalzano,et al.  Nuclear Shape Changes Are Induced by Knockdown of the SWI/SNF ATPase BRG1 and Are Independent of Cytoskeletal Connections , 2013, PLoS ONE.

[23]  M. Mayo,et al.  Global Epigenetic Changes Induced by SWI2/SNF2 Inhibitors Characterize Neomycin-Resistant Mammalian Cells , 2012, PloS one.

[24]  K. Nishiguchi,et al.  Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin , 2012, Oncology letters.

[25]  S. Knapp,et al.  Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.

[26]  J. Settleman,et al.  Mechanisms of acquired resistance to targeted cancer therapies. , 2012, Future oncology.

[27]  E. Chowdhury,et al.  Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs , 2012, International journal of nanomedicine.

[28]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[29]  Qing-quan Li,et al.  Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. , 2011, International journal of oncology.

[30]  Raymond K. Auerbach,et al.  Diverse Roles and Interactions of the SWI/SNF Chromatin Remodeling Complex Revealed Using Global Approaches , 2011, PLoS genetics.

[31]  K. Moitra,et al.  Evolution of ABC transporters by gene duplication and their role in human disease , 2011, Biological chemistry.

[32]  S. Semba,et al.  Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells , 2010, British Journal of Cancer.

[33]  G. Viale,et al.  Management of triple negative breast cancer. , 2010, Breast.

[34]  M. Martinka,et al.  BRG1 expression is increased in human cutaneous melanoma , 2010, The British journal of dermatology.

[35]  V. Weaver,et al.  SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells , 2010, Journal of cellular physiology.

[36]  G. Crabtree,et al.  Chromatin remodelling during development , 2010, Nature.

[37]  Ting Wang,et al.  ENCODE whole-genome data in the UCSC Genome Browser , 2009, Nucleic Acids Res..

[38]  Tanja Cufer,et al.  The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy , 2009, Breast Cancer Research and Treatment.

[39]  E. Androphy,et al.  The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells , 2009, Oncogene.

[40]  P. Ruff,et al.  A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen , 2009, Cancer Chemotherapy and Pharmacology.

[41]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[42]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[43]  Heshui Wu,et al.  Persistence of side population cells with high drug efflux capacity in pancreatic cancer. , 2008, World journal of gastroenterology.

[44]  R. Kingston,et al.  The HSA Domain of BRG1 Mediates Critical Interactions Required for Glucocorticoid Receptor-Dependent Transcriptional Activation In Vivo , 2007, Molecular and Cellular Biology.

[45]  H. Blum,et al.  Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs , 2007, Cancer Gene Therapy.

[46]  O. Tawfik,et al.  Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers , 2007, The Prostate.

[47]  R. Ueda,et al.  MRP8/ABCC11 directly confers resistance to 5-fluorouracil , 2007, Molecular Cancer Therapeutics.

[48]  Manfred Dietel,et al.  ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome , 2006, Clinical Cancer Research.

[49]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[50]  Y. Ohkawa,et al.  The Microphthalmia-associated Transcription Factor Requires SWI/SNF Enzymes to Activate Melanocyte-specific Genes* , 2006, Journal of Biological Chemistry.

[51]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[52]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[53]  M. Gottesman,et al.  The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research , 2006, FEBS letters.

[54]  M. Fu,et al.  [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line]. , 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[55]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Tapscott,et al.  MyoD Targets Chromatin Remodeling Complexes to the Myogenin Locus Prior to Forming a Stable DNA-Bound Complex , 2005, Molecular and Cellular Biology.

[58]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[59]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[60]  T. Archer,et al.  Reconstitution of Glucocorticoid Receptor-Dependent Transcription In Vivo , 2004, Molecular and Cellular Biology.

[61]  Zhe-Sheng Chen,et al.  MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine* , 2003, Journal of Biological Chemistry.

[62]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[63]  H. Yokozaki,et al.  Increased Expression but Not Genetic Alteration of BRG1, a Component of the SWI/SNF Complex, Is Associated with the Advanced Stage of Human Gastric Carcinomas , 2002, Pathobiology.

[64]  C. Peterson,et al.  The bromodomain: a regulator of ATP-dependent chromatin remodeling? , 2001, Frontiers in bioscience : a journal and virtual library.

[65]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[66]  D. Slamon,et al.  New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). , 2001, Seminars in oncology.

[67]  A. Imbalzano,et al.  Phosphoaminoglycosides inhibit SWI2/SNF2 family DNA-dependent molecular motor domains. , 2000, Biochemistry.

[68]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[69]  R. Kreitman Immunotoxins for targeted cancer therapy. , 1998, The AAPS journal.

[70]  M. Barinaga From Bench Top to Bedside , 1997, Science.

[71]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[72]  M. Yaniv,et al.  Purification and biochemical heterogeneity of the mammalian SWI‐SNF complex. , 1996, The EMBO journal.

[73]  H. Chiba,et al.  Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. , 1994, Nucleic acids research.

[74]  Paul A. Khavari,et al.  BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription , 1993, Nature.

[75]  M. Yaniv,et al.  A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. , 1993, The EMBO journal.

[76]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[77]  J. G. Cory,et al.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. , 1991, Cancer communications.

[78]  D. Housman,et al.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues , 1989, Molecular and cellular biology.

[79]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[81]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[82]  R. Noble,et al.  Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. , 1960, Cancer research.

[83]  A. Gilman,et al.  The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. , 1946, Science.

[84]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[85]  N. Cherdyntseva,et al.  Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response , 2012, Cancer Chemotherapy and Pharmacology.

[86]  Jiang Wu Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. , 2012, Acta biochimica et biophysica Sinica.

[87]  D. Keppler,et al.  Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. , 2011, Handbook of experimental pharmacology.

[88]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[89]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[90]  Aris Persidis,et al.  Cancer multidrug resistance , 1999, Nature Biotechnology.

[91]  L. Greenberger,et al.  Alternate overexpression of two P-glycoprotein [corrected] genes is associated with changes in multidrug resistance in a J774.2 cell line. , 1989, The Journal of biological chemistry.